As reported earlier this year, the Beijing Genomics Institute (now BGI) and GT Life Sciences (and founder Bernard Paulssen) have been working on the CHO genome sequence. Today, they report completing the sequence of CHO K1 for the first time.
Says Paulssen, "This newly available knowledge will bring multiple benefits including media optimization and improved cell growth, protein production, glycosylation and cell-line engineering. Ultimately, it brings genome-scale science to CH)-based production and biopharmaceuticals." Paulssen expects the availability of the sequence with a scale model of CHO metabolism to provide a powerful tool for the development of the next generation of biopharmaceutical processing technologies.
BGI and GT plan to work closely to annotate the sequence data and to provide an interpretation of genetic regulation in cell proliferation. They also plan to sequence other CHO cell lines like DG44 or Dux-B11.
Read here for the full press release issued by both companies today.
Posted by Bruce Lehr Jan 6th 2011.